Compounds · Tirzepatide · continued

[2026 update] Does dual agonism explain the effect size, or is it dose? posts 61–64

Compounds › Tirzepatide SURMOUNT programme randomised trial SURPASS programme effect size Solved

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.

b.okonkwoTL2 Moderator1 Nov 2025#61

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

29 likes 9mo

f.amankwahTL2 Moderator2 Nov 2025#62

Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.

0 likes 9mo

hana.satoTL43 Nov 2025#63

Collapsed as off-topic by two members at trust level 3 or above

This follows post #60 rather than contradicting it.

The 2.5 mg starting dose is not a therapeutic dose in the sense that weight loss is minimal at that dose. It is a tolerance-testing dose. Confusing the purpose of a starting dose with the purpose of a maintenance dose leads to false conclusions about efficacy.

c.ostergaardTL2 Moderator4 Nov 2025#64

s.dziedzic, post #33: Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do. Go to post

I read post #62 twice before replying, because I had assumed the opposite.

9 likes in reply to #33 9mo

This topic was referenced in

About the Tirzepatide categoryCompounds › Tirzepatide · 6 replies
Comparing tirzepatide and semaglutide is harder than the tables suggestCompounds › Tirzepatide · 2 replies
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long versionCompounds › Tirzepatide · 90 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
About the Tirzepatide category Compounds › Tirzepatide tirzepatide SURMOUNT programme SURPASS programme Pinned Wiki Dual GIP/GLP-1 receptor agonist. SURPASS and SURMOUNT programme data, titration, and comparative discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+2	6	132	13mo
Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? Compounds › Tirzepatide SURMOUNT programme SURPASS programme effect size tirzepatide Asking directly, because I could not find a straight answer: Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? Comparing STEP 2 ( Lancet , 2021) with…	+7	11	281	6mo
Does dual agonism explain the effect size, or is it dose? Compounds › Tirzepatide SURPASS programme SURMOUNT programme tirzepatide randomised trial Solved Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SURPASS-4 ( Lancet , 2021). Please read it…	+62	68	2.6k	29d
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Compounds › Tirzepatide SURMOUNT programme randomised trial effect size tirzepatide Closed On the subject in the title: Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med ,…	+85	90	13k	7mo
The 2.5 mg starting dose is not a therapeutic dose — why that matters Compounds › Tirzepatide SURPASS programme SURMOUNT programme effect size Solved The 2.5 mg starting dose is not a therapeutic dose — why that matters Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016). Please…	+119	136	5.6k	2mo

Related topics — sharing the tags SURMOUNT programme, randomised trial, SURPASS programme

Topic	Participants	Replies	Views	Activity
Tirzepatide and nausea: is the profile genuinely different or just differently reported? Compounds › Tirzepatide SURMOUNT programme randomised trial SURPASS programme tirzepatide Asking directly, because I could not find a straight answer: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Comparing PIONEER 6 ( N Engl J Med , 2019) with STEP 8 (…	+18	22	37k	8mo
Why retatrutide discussion here is more cautious than elsewhere — one year on Compounds › Retatrutide TRIUMPH programme effect size preprint retatrutide Asking directly, because I could not find a straight answer: Why retatrutide discussion here is more cautious than elsewhere — one year on Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it…	+92	97	3.6k	20h
Why retatrutide discussion here is more cautious than elsewhere Compounds › Retatrutide randomised trial effect size retatrutide preprint Solved Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited…	+7	12	7.7k	2mo
Non-inferiority margins: how they are chosen and how they are abused — a second dataset Evidence › Trials randomised trial discontinuation & dropout intention to treat estimand Non-inferiority margins: how they are chosen and how they are abused — a second dataset — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with…	+32	37	574	5mo
Comparing my trajectory with the trial curves, carefully Outcomes › Progress reports DXA effect size long read data table Solved Posting this under the heading it deserves: Comparing my trajectory with the trial curves, carefully Everything below is what sits behind that. Maintenance rather than loss, which is the part of this that…	+86	92	54k	7mo